Technology
Health
Pharmaceutical
Hutchison China Meditech
$26.869876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$26.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.12 (0.45%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell HCM and other stocks, options, ETFs, and crypto commission-free!
About
Hutchison China MediTech Limited American Depositary Shares, also called Hutchison China Meditech, is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. Read More The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.
Employees
714
Headquarters
Hong Kong, Central & Western
Founded
2000
Market Cap
3.56B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
222.60K
High Today
$27.53
Low Today
$26.63
Open Price
$26.67
Volume
55.35K
52 Week High
$39.68
52 Week Low
$20.83
Collections
Technology
Health
Pharmaceutical
Research And Development
Consumer Products
Therapy
Advertising and Marketing
Retail
News
Yahoo FinanceApr 26
Did Hedge Funds Drop The Ball On Hutchison China MediTech Limited (HCM) ?
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of a value discipline will be in avoiding the biggest capital-destroying rocks. If a rock emerges on the crowded shore of U.S. momentum, it could result in a major liquidity challenge, as mo...
Seeking AlphaApr 21
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
CASI, a US in-licensing pharma with operations in China, acquired global rights to an investigational anti-CD38 immunotherapy from Black Belt Therapeutics of the UK. Hutchison China MediTech (Chi-Med) filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. Deals and Financings Hutchison China MediTech (Chi-Med) [AIM:HCM] (NASDAQ:HCM) filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, wher...
Price Paid on Robinhood
0% Lower
Right Now
52 Week Low
$20.83
Average Price Paid
$26.97
52 Week High
$39.68
Earnings
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
—